Navy wants to test drinking water for synthetic chemicals near Chesapeake's Northwest Annex
CHESAPEAKE — The U.S. Navy is asking Chesapeake residents who live within a mile of the Northwest Annex to reach out and have their drinking water wells sampled for certain long-lasting synthetic chemicals.
The Navy is testing for per- and polyfluoroalkyl substances, or PFAS, which are a combination of thousands of different chemicals that have been commonly used in household and industrial products for decades, particularly due to stain- and water-repellent qualities.
The chemicals tend to stick around for a long time. So the Navy and Department of Defense have developed policies to address past releases of PFAS at its installations nationwide.
At the Northwest Annex, the previous use of firefighting foam for testing, training, firefighting and other activities resulted in PFAS being present in the groundwater there, prompting the need to sample nearby drinking water wells located in the direction the groundwater flows away from the Northwest Annex.
The Northwest Annex includes various support services for the Navy, U.S. Coast Guard, Department of Homeland Security, U.S. Marine Corps Anti-Terrorism/Force Protection and NATO. It also operates the largest small-arms range facilities in Navy Region Mid-Atlantic.
RFK Jr.'s MAHA report raises concerns about vaccines, American foods and prescription drugs
FDA panel debates COVID vaccine recipe as questions swirl about fall shots
Measles is very contagious. Here's how to avoid it
For kids with autism, swim classes can be lifesaving
Markers in blood and urine may reveal how much ultraprocessed food we are eating
In 2024, the Environmental Protection Agency released new regulations and standards for PFAS in drinking water as part of the Safe Water Drinking Act. Also in 2024, the Department of Defense published plans about ongoing PFAS cleanups, with priority to address private drinking water wells with the highest levels of PFAS from military activities.
Exposure to certain levels of PFAS has been linked to certain types of cancer, including prostate, kidney and testicular. It could also decrease fertility, cause developmental effects in children and weaken the immune system.
The Navy tested homes located near Northwest Annex in 2019, and no homes met the levels established at that time that called for remediation, according to the Environmental Restoration Program. But now armed with new standards, the Navy is again testing homes within a mile-stretch along the Northwest River and near the Virginia state line, including those already tested in 2019. Using new levels, the Navy has already determined one home tested in 2019 reached a level that calls for an 'enduring solution.'
The Navy has offered similar testing for residents near St. Juliens Creek Annex in Chesapeake.
Appointments can be made and eligibility can be determined by calling 833-692-6639. More information can be found here.
Preliminary sample results are expected within 30 days of collection. The Navy will follow up with property owners and address next steps if needed, which could involve an 'enduring solution' like the installation of a drinking water treatment system if levels are detected above 70 parts per trillion.
Natalie Anderson, 757-732-1133, natalie.anderson@virginiamedia.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
24 minutes ago
- Associated Press
Catheter Precision (VTAK) Reports Key Progress for the LockeT Product
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 2025 LockeT sales are already outpacing Q2 2024 sales with a 200% increase. Catheter Precision now has several US hospitals that are on track to issue more than $100,000 in purchase orders each for LockeT by the end of 2025. These hospitals include Montefiore (Bronx, NY), Eisenhower Health (Rancho Mirage, CA), and Overland Park Regional Medical Center (Overland Park, KS). As previously announced, LockeT received the CE Mark enabling sales in Europe. Catheter Precision has secured a new distributor in Italy and anticipates additional distributors in the coming days for Spain, Portugal and the UK and is actively searching for the right partner is other EU countries. David Jenkins, CEO of Catheter Precision said, 'We are excited about the upcoming activities, sales pipeline and expanded use by existing customer to increase revenue generated by LockeT. At this time, there is a live case scheduled on Monday, Juen 16 with a key opinion leader where he will demonstrate LockeT during an Italian symposium, increasing its awareness to the new market. As a company, we continue to focus on improving product awareness, increasing product usage and expanding our footprint into Europe.' About LockeT Catheter Precision's LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval. About Catheter Precision Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Cautionary Note Regarding Forward-Looking Statements Statements in this press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as 'believe,' 'anticipate,' 'may,' 'might,' 'can,' 'could,' 'continue,' 'depends,' 'expect,' 'expand,' 'forecast,' 'intend,' 'predict,' 'plan,' 'rely,' 'should,' 'will,' 'may,' 'seek,' or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption 'Risk Factors' in the Company's Form 10-K filed with the SEC and available at The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. CONTACTS: At the Company David Jenkins 973-691-2000 [email protected] # # #
Yahoo
28 minutes ago
- Yahoo
Analysis-Kennedy's ouster of US vaccine advisers puts pharma ties under scrutiny
By Chad Terhune (Reuters) -U.S. Health Secretary Robert F. Kennedy Jr.'s surprise ouster of a national vaccine advisory board, claiming it was "plagued with persistent conflicts of interest," puts new scrutiny on the group that recommends which shots should be administered to the American public. Kennedy said most vaccine experts on the 17-member Advisory Committee on Immunization Practices (ACIP) have received "substantial funding" from drugmakers. He did not provide examples of conflicts of interest for any individual adviser or say how that may have influenced specific recommendations. Committee members say their work with the U.S. Centers for Disease Control and Prevention follows rigorous vetting of their financial ties. They must abstain from votes on any vaccine for which they have a conflict, as well as any rival to that vaccine or any product from the same manufacturer, according to CDC rules. The agency's website lists one of the departing panel members as recusing herself over such conflicts. "To determine that the whole (advisory board), all 17 members, have conflicts of interest, that has not been shown by the evidence," fired board member Dr. Oliver Brooks told Reuters. "However, the decisions that have been made (by Kennedy) undermine confidence in the process and in vaccines." Six of the vaccine advisers fired by Kennedy received a total of $80 or less from drugmakers from 2017 to 2023, according to a Reuters review of the Open Payments federal database of industry payments to healthcare providers. Seven other panel members received between $4,000 and $55,000 from drugmakers for consulting, speaking fees, travel or meals over the period 2017 to 2023. Two of those experts had also worked with other scientists in industry-funded research projects worth several millions of dollars. Brooks, retired chief medical officer at Watts Healthcare in Los Angeles and former president of the National Medical Association, received nearly $44,000 in general payments from Sanofi, according to the government records. Most of the payments occurred in 2017 and 2018, with nothing after 2020. Brooks became a vaccine adviser in 2021, and did not disclose any conflicts that would preclude him from voting. He said the panel's sole aim is "to prevent vaccine-preventable illness." Sanofi declined to comment. At least three vaccine advisers were not health professionals tracked by mandatory Open Payments reporting. KENNEDY'S CONFLICT Kennedy, who has spent years sowing doubts about vaccine safety and efficacy contrary to scientific evidence, faced questions from Congress about his own potential conflicts of interest during a confirmation hearing. Kennedy said he would divest his financial interest in litigation against Merck over its Gardasil vaccine, which prevents cancers caused by the human papillomavirus, to his non-dependent, adult son. In posts on X this week, Kennedy said he would share "examples of the historical corruption at ACIP" and announced eight new panel members. Four of them had received nominal reimbursement for meals, according to Open Payments, while the remainder recorded no payments or weren't covered by the database. A 2009 federal inspector general's report criticized the CDC for lax enforcement of disclosures among its advisory panels. New research shared with Reuters suggests conflicts have since declined among vaccine board members. "People are more aware of these issues on advisory committees, so they're facing greater scrutiny there," said Dr. Genevieve Kanter, an associate professor of public policy at the University of Southern California who has studied conflicts among government health advisers. Kanter's analysis of vaccine panel disclosures found that, on average, 43% of panel members facing decisions on specific vaccines declared conflicts in 2000 compared to 5%, on average, at meetings over the last 10 years. Kanter said it will also be important to understand how the vaccine advisers assembled by Kennedy are vetted for conflicts. They are due to meet at the end of June. "We don't want to replace one conflict with another set of conflicts," she said. "If someone has a financial interest in treatments that are believed to be alternatives to vaccines for certain conditions, we want to know that." DISCLOSURE RULES ACIP members are required to divest all stock in vaccine makers and stop any active consulting work for those companies before joining the panel. They can't accept travel or food from vaccine companies or collect product royalties. Similar restrictions apply to family members. Committee members can keep working on vaccine clinical trials funded by industry and those research grants can help cover their salaries. They are required to file annual disclosures and recuse themselves from votes when specific conflicts arise. "ACIP members ... are carefully screened for major conflicts of interest and selected through a lengthy process," said the California Department of Public Health, whose immunization chief, Dr. Robert Schechter, was fired from the panel by Kennedy. One of the fired panel members, Dr. Bonnie Maldonado, is a pediatric infectious diseases specialist at Stanford University who has led vaccine studies worldwide. She participated in research that received $4.65 million in funding from Pfizer, most of it spanning 2021 to 2023. The studies involved vaccines for COVID-19, RSV and other diseases. Maldonado also received general payments from drugmakers, including $26,465 from Pfizer and nearly $7,000 from Merck. Maldonado abstained from a vote on COVID vaccine recommendations in June 2024, declaring a conflict of interest. In October, she did participate in a COVID-related vote. Maldonado didn't respond to a request for comment. Noel Brewer, a professor of public health at the University of North Carolina, is not a clinician and therefore not included in Open Payments. In a 2017 research paper, he disclosed receiving research grants from Merck, Pfizer and GSK and serving on a paid advisory board for Merck. The disclosures did not give details on the payment amounts. Spokespeople for the three vaccine makers were not immediately available for comment.
Epoch Times
an hour ago
- Epoch Times
The Real Epidemic Is the Chronic Disease Crisis
Commentary When COVID-19 swept across the globe, governments shut down businesses, closed schools, and confined people to their homes. We were told it was all to 'save lives.' But I couldn't help asking: Whose lives, and at what cost? For a virus with a survival rate over 99 percent for the vast majority—especially those under 50—we disrupted nearly every aspect of society. And yet, the real epidemic—the one driven by processed food, inactivity, artificial environments, and chronic stress—continues to take millions of lives each year with far less urgency or attention.
